Name

Riva Therapeutics

Legal name

Riva Therapeutics

Website

https://rivatherapeutics.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Marketing channels2 records

Core offering

Riva Therapeutics is a precision oncology company developing a new generation of "precision lethal" small molecule therapeutics for cancer treatment. The company leverages deep knowledge of genomic dependencies to selectively target essential tumor cell processes beyond DNA damage repair, aiming to treat approximately one-third of all cancer patients. The portfolio emerged from a 4-year research collaboration with the Broad Institute of MIT and Harvard and targets a subset of essential oncogenic processes previously thought to be "undruggable."

Product overview

Riva Therapeutics develops precision lethal small molecule therapeutics for precision oncology treatment. Their portfolio, developed through a 4-year collaboration with the Broad Institute of MIT and Harvard, focuses on targeting essential tumor cell processes beyond DNA damage repair. The company leverages deep knowledge of genomic dependencies to selectively target synthetic lethal interactions, resulting in selective tumor cell death while sparing healthy cells. No specific named drug products or modules are identified in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision Lethal Small Molecule Therapeutics Portfolio A portfolio of small molecule precision lethal oncology therapeutics that leverage synthetic lethal interactions beyond DNA damage repair to selectively kill tumor cells while sparing healthy normal cells; targets essential oncogenic processes including a subset previously thought to be "undruggable." Intended for eventual commercialization through standard pharmaceutical channels upon regulatory approval, targeting approximately one-third of all cancer patients.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Broad Institute of MIT and HarvardcoreStrategic or Co-development PartnerRiva's portfolio is the result of a 4-year collaboration with the Broad Institute. The Research Alliance evolved from the Novo Broad Greenhouse, a joint initiative between Novo Ventures and the Broad Institute. The partnership provides access to proprietary platform technologies, world-class cancer biology expertise, and continued insights from scientific co-founders William C. Hahn, MD, PhD; Francisca Vazquez, PhD; Andrew Aguirre, MD, PhD; Kent Mouw, MD, PhD; Eliezer Van Allen, MD; and Peter Tsvetkov, PhD.

Recent moves5 records

Expansion highlights4 records

Direct peers

• Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology company developing small molecule therapies against oncogenic driver mutations and previously undruggable targets, sharing Riva's focus on tackling hard-to-drug cancer biology with small molecules.
• Tango Therapeutics: Tango Therapeutics is a precision oncology company developing synthetic-lethality small molecule therapies targeting tumor-specific genetic dependencies, closely matching Riva's core approach of leveraging genomic dependencies to selectively kill cancer cells.
• Relay Therapeutics: Relay Therapeutics is a precision oncology company using motion-based protein design to develop small molecule therapies against validated oncogenic targets, comparable to Riva in patient-stratified, genomics-informed oncology drug development.
• Foghorn Therapeutics: Foghorn Therapeutics targets chromatin regulatory biology in oncology with small molecule drug discovery, sharing Riva's small-molecule, genomics-guided approach to previously difficult cancer targets.
• Repare Therapeutics: Repare Therapeutics is a precision oncology company built around synthetic lethality and genome-wide CRISPR screens to develop small molecule therapies against genetically defined tumor populations, directly comparable to Riva's precision lethal approach.
• Accent Therapeutics: Accent Therapeutics is a precision oncology company developing small molecule therapies targeting RNA-modifying proteins and other oncogenic dependencies in cancer, comparable to Riva in modality (small molecule) and genomic-dependency-driven target selection.

Emerging players

• Arvinas: Arvinas pioneered targeted protein degradation (PROTAC) small molecules against oncology targets, sharing Riva's small-molecule, oncology-focused, dependency-driven modality but via a distinct catalytic mechanism.
• Kronos Bio: Kronos Bio is a clinical-stage precision oncology company developing small molecule therapies against transcription factor and other challenging oncology targets, sharing Riva's mission to drug previously undruggable cancer biology.
• Kymera Therapeutics: Kymera Therapeutics is an oncology-focused targeted protein degradation company developing small molecule therapies against disease-driving proteins, sharing Riva's small-molecule precision oncology positioning but using a distinct catalytic mechanism.

Others

• Schrödinger: Schrödinger provides computational drug discovery platforms used by many precision oncology companies, including tools for dependency mapping and small molecule design; it is an enabling technology peer rather than a direct therapeutic competitor to Riva.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/riva-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Riva Therapeutics